Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568192 | 1.00 | MEN1 (0.50) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL5568190 | 1.00 | MEN1 (0.50) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL31309182 | 1.00 | MEN1 (0.50) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL8269795 | 1.00 | MEN1 (0.50) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL16589450 | 0.88 | ALDH1A1 (0.49) | POLBMAPTALDH1A1MAOAMAOB | |
| SCHEMBL16592217 | 0.87 | NPFFR1 (0.49) | MAPTALDH1A1L3MBTL1ATMKDM4E | |
| SCHEMBL11147455 | 0.87 | MEN1 (0.55) | MEN1KMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL24938939 | 0.86 | CYP3A4 (0.50) | KMT2AMAPTALDH1A1KDM4EMAOA | |
| SCHEMBL4249938 | 0.86 | CYP3A4 (0.50) | KMT2AMAPTALDH1A1KDM4EMAOA | |
| SCHEMBL15325590 | 0.86 | CYP3A4 (0.50) | KMT2AMAPTALDH1A1KDM4EMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1751099-A1 | CIS PYRROLIDINYL DERIVATIVES AND THEIR USES | Faust Pharmaceuticals (FR) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118533-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118534-A1 | CIS PYRROLIDINYL DERIVATIVES AND THEIR USES | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118534-A1 | CIS PYRROLIDINYL DERIVATIVES AND THEIR USES | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | MEN1 796/4885KMT2A 5/4885POLB 1034/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | MEN1 796/4885KMT2A 5/4885POLB 1034/4885 |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | SUCNR1, GLRA1, CNR1 | MEN1 3600/4885KMT2A 3550/4885POLB 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.